questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Antirhumatismaux
Antirhumatismaux : Questions médicales fréquentes
Diagnostic
5
Maladies rhumatismales
Diagnostic médical
Tests diagnostiques
Imagerie par résonance magnétique
Symptômes
Douleur articulaire
Protéine C-réactive
Inflammation
Évaluation de la douleur
Fonctionnalité
Symptômes
5
Variabilité des symptômes
Patients
Complications
Évolution de la maladie
Prévention
5
Prévention
Exercice physique
Tabagisme
Facteurs de risque
Activité physique
Mobilité
Alimentation
Antioxydants
Stress
Gestion de la douleur
Traitements
5
Médecine personnalisée
Traitement
Effets secondaires
Infections
Suivi médical
Ajustement du traitement
Complications
5
Complications
Dommages articulaires
Signes cliniques
Infection
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Facteurs environnementaux
Produits chimiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antirhumatismaux : Questions médicales les plus fréquentes",
"headline": "Antirhumatismaux : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antirhumatismaux : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-04",
"dateModified": "2025-11-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antirhumatismaux"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Utilisations thérapeutiques",
"url": "https://questionsmedicales.fr/mesh/D045506",
"about": {
"@type": "MedicalCondition",
"name": "Utilisations thérapeutiques",
"code": {
"@type": "MedicalCode",
"code": "D045506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anti-inflammatoires non stéroïdiens",
"alternateName": "Anti-Inflammatory Agents, Non-Steroidal",
"url": "https://questionsmedicales.fr/mesh/D000894",
"about": {
"@type": "MedicalCondition",
"name": "Anti-inflammatoires non stéroïdiens",
"code": {
"@type": "MedicalCode",
"code": "D000894",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.030"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des cyclooxygénases",
"alternateName": "Cyclooxygenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D016861",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des cyclooxygénases",
"code": {
"@type": "MedicalCode",
"code": "D016861",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.030.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cyclooxygénase 2",
"alternateName": "Cyclooxygenase 2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D052246",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2",
"code": {
"@type": "MedicalCode",
"code": "D052246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.030.500.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cyclooxygénase 2",
"alternateName": "Cyclooxygenase 2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D052246",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2",
"code": {
"@type": "MedicalCode",
"code": "D052246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.030.500.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Antigoutteux",
"alternateName": "Gout Suppressants",
"url": "https://questionsmedicales.fr/mesh/D006074",
"about": {
"@type": "MedicalCondition",
"name": "Antigoutteux",
"code": {
"@type": "MedicalCode",
"code": "D006074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.337"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Uricosuriques",
"alternateName": "Uricosuric Agents",
"url": "https://questionsmedicales.fr/mesh/D014528",
"about": {
"@type": "MedicalCondition",
"name": "Uricosuriques",
"code": {
"@type": "MedicalCode",
"code": "D014528",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.337.900"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Antirhumatismaux",
"alternateName": "Antirheumatic Agents",
"code": {
"@type": "MedicalCode",
"code": "D018501",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Morten Wang Fagerland",
"url": "https://questionsmedicales.fr/author/Morten%20Wang%20Fagerland",
"affiliation": {
"@type": "Organization",
"name": "Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway."
}
},
{
"@type": "Person",
"name": "Ivana Hollan",
"url": "https://questionsmedicales.fr/author/Ivana%20Hollan",
"affiliation": {
"@type": "Organization",
"name": "Beitostølen Health and Sport Centre, Beitostølen, Norway."
}
},
{
"@type": "Person",
"name": "Gunnbjørg Hjeltnes",
"url": "https://questionsmedicales.fr/author/Gunnbj%C3%B8rg%20Hjeltnes",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Innlandet Hospital Trust, Lillehammer, Norway."
}
},
{
"@type": "Person",
"name": "Stefan Agewall",
"url": "https://questionsmedicales.fr/author/Stefan%20Agewall",
"affiliation": {
"@type": "Organization",
"name": "University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer].",
"datePublished": "2023-02-09",
"url": "https://questionsmedicales.fr/article/36757415",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00393-023-01316-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis.",
"datePublished": "2023-10-02",
"url": "https://questionsmedicales.fr/article/37801318",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2023.35950"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.",
"datePublished": "2023-06-20",
"url": "https://questionsmedicales.fr/article/37334513",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3904/kjim.2022.369"
}
},
{
"@type": "ScholarlyArticle",
"name": "Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: a systematic review.",
"datePublished": "2023-03-30",
"url": "https://questionsmedicales.fr/article/36991244",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10067-023-06587-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Offspring neurodevelopmental outcomes born to parents with chronic inflammatory arthritis using antirheumatic therapies: A scoping review.",
"datePublished": "2023-06-02",
"url": "https://questionsmedicales.fr/article/37295300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.semarthrit.2023.152230"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antirhumatismaux",
"item": "https://questionsmedicales.fr/mesh/D018501"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antirhumatismaux - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antirhumatismaux",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antirhumatismaux",
"description": "Comment diagnostiquer une maladie rhumatismale ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes indiquent une maladie rhumatismale ?\nLes marqueurs inflammatoires sont-ils utiles ?\nComment évaluer la gravité de la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D018501#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antirhumatismaux",
"description": "Quels sont les symptômes courants des maladies rhumatismales ?\nLa raideur matinale est-elle un symptôme clé ?\nLes symptômes varient-ils selon les patients ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?\nLes symptômes affectent-ils la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D018501#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antirhumatismaux",
"description": "Peut-on prévenir les maladies rhumatismales ?\nLe tabagisme influence-t-il les maladies rhumatismales ?\nL'activité physique est-elle bénéfique ?\nUne alimentation anti-inflammatoire est-elle recommandée ?\nLe stress a-t-il un impact sur les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D018501#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antirhumatismaux",
"description": "Quels types d'antirhumatismaux existent ?\nComment les DMARDs agissent-ils ?\nLes traitements sont-ils personnalisés ?\nQuels effets secondaires peuvent survenir ?\nLes traitements nécessitent-ils un suivi régulier ?",
"url": "https://questionsmedicales.fr/mesh/D018501#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antirhumatismaux",
"description": "Quelles sont les complications possibles des maladies rhumatismales ?\nLes maladies rhumatismales peuvent-elles affecter d'autres organes ?\nComment prévenir les complications ?\nLes complications peuvent-elles être réversibles ?\nQuels signes indiquent une complication ?",
"url": "https://questionsmedicales.fr/mesh/D018501#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antirhumatismaux",
"description": "Quels sont les principaux facteurs de risque ?\nL'obésité est-elle un facteur de risque ?\nLes infections peuvent-elles déclencher des maladies rhumatismales ?\nLe sexe influence-t-il le risque de maladie ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D018501#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie rhumatismale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, les antécédents médicaux et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses de sang, des radiographies et parfois des IRM sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une maladie rhumatismale ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleurs articulaires, raideur matinale, fatigue et gonflement des articulations."
}
},
{
"@type": "Question",
"name": "Les marqueurs inflammatoires sont-ils utiles ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme la protéine C-réactive aident à évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment évaluer la gravité de la maladie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des échelles de douleur et des tests fonctionnels."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des maladies rhumatismales ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleurs, raideurs, gonflements et fatigue sont fréquents."
}
},
{
"@type": "Question",
"name": "La raideur matinale est-elle un symptôme clé ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la raideur matinale qui dure plus d'une heure est significative."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la durée des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les symptômes peuvent s'aggraver et entraîner des complications."
}
},
{
"@type": "Question",
"name": "Les symptômes affectent-ils la qualité de vie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur et la fatigue peuvent significativement réduire la qualité de vie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies rhumatismales ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures comme l'exercice régulier et une alimentation saine peuvent aider."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les maladies rhumatismales ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque qui peut aggraver les symptômes."
}
},
{
"@type": "Question",
"name": "L'activité physique est-elle bénéfique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité physique régulière peut améliorer la mobilité et réduire la douleur."
}
},
{
"@type": "Question",
"name": "Une alimentation anti-inflammatoire est-elle recommandée ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en oméga-3 et en antioxydants peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et affecter la gestion de la douleur."
}
},
{
"@type": "Question",
"name": "Quels types d'antirhumatismaux existent ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il existe des anti-inflammatoires, des DMARDs et des biologiques."
}
},
{
"@type": "Question",
"name": "Comment les DMARDs agissent-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les DMARDs modifient la progression de la maladie et réduisent l'inflammation."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement est souvent adapté en fonction des besoins individuels."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des nausées, des éruptions cutanées et des infections."
}
},
{
"@type": "Question",
"name": "Les traitements nécessitent-ils un suivi régulier ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des maladies rhumatismales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des dommages articulaires, des maladies cardiovasculaires et des infections."
}
},
{
"@type": "Question",
"name": "Les maladies rhumatismales peuvent-elles affecter d'autres organes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent toucher le cœur, les poumons et les reins, entraînant des complications."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce et un suivi régulier aident à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs accrues, de la fièvre ou des signes d'infection peuvent indiquer une complication."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe féminin, des antécédents familiaux et le tabagisme."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité augmente le risque de développer des maladies rhumatismales."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles déclencher des maladies rhumatismales ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent précipiter l'apparition de maladies rhumatismales."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de maladie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont généralement plus à risque de développer des maladies rhumatismales."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de maladies rhumatismales."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/11/2025
Contenu vérifié selon les dernières recommandations médicales
11 publications dans cette catégorie
Publications dans "Antirhumatismaux" :
3 publications dans cette catégorie
Affiliations :
Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway.
Publications dans "Antirhumatismaux" :
3 publications dans cette catégorie
Affiliations :
Beitostølen Health and Sport Centre, Beitostølen, Norway.
Norwegian University of Science and Technology, Gjøvik, Norway.
Publications dans "Antirhumatismaux" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Innlandet Hospital Trust, Lillehammer, Norway.
Publications dans "Antirhumatismaux" :
3 publications dans cette catégorie
Affiliations :
University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway.
Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway.
Publications dans "Antirhumatismaux" :
3 publications dans cette catégorie
Affiliations :
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Division of Rheumatology, University of Washington.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Children's of Alabama and Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Programmbereich Epidemiologie und Versorgungsforschung, Deutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. albrecht@drfz.de.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Department of Laboratory medicine, Innlandet Hospital Trust, Lillehammer, Norway.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Volvat Medical Center, Lillehammer, Norway.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Professor, Division of Infectious Diseases, Oregon Health and Science University, Portland, OR.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Professor, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL jrcurtis@uabmc.edu.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Department of Laboratory Medicine, Vestre Viken Trust, Drammen, Norway.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine & Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, National Taiwan University Hospital, 7 Chung Shan S Rd, Taipei, 10048, Taiwan. tftsai@yahoo.com.
Department of Dermatology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, Taiwan. tftsai@yahoo.com.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Northwestern Medicine, Chicago, Illinois, United States.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States.
Publications dans "Antirhumatismaux" :
2 publications dans cette catégorie
Affiliations :
George Washington University School of Medicine and Health Sciences, Washington, DC, United States.
Publications dans "Antirhumatismaux" :
In contrast to the original fear that treatment with disease-modifying antirheumatic drugs (DMARDs) and especially with biologic DMARDs (bDMARDs), was associated with an increased risk of the inductio...
This is the first network meta-analysis to assess outcomes associated with multiple conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid....
To analyze clinical outcomes after treatment with conventional synthetic disease-modifying antirheumatic drugs and glucocorticoid among patients with rheumatoid arthritis....
With no time restraint, English language articles were searched in MEDLINE, Embase, Cochrane Central, ClinicalTrials.gov, and reference lists of relevant meta-analyses until September 15, 2022....
Four reviewers in pairs of 2 independently included controlled studies randomizing patients with rheumatoid arthritis to mono-conventional synthetic disease-modifying antirheumatic drugs, glucocortico...
The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline, and data quality was assessed by the Cochrane risk of bias tool RoB 2. Data were extract...
A protocol with hypothesis and study plan was registered before data recording. The most complete of recorded outcomes (tender joint count) was used as primary outcome, with imputations based on other...
A total of 29 interventions in 275 treatment groups among 132 randomized clinical trials (mean [range], 71.0% [27.0% to 100%] females in studies; mean [range] of ages in studies, 53 [36 to 70] years) ...
This study's results support the present role of methotrexate as the primary reference conventional synthetic disease-modifying antirheumatic drug....
We aimed to compare the effectiveness and safety of Janus kinase inhibitors (JAKi) vs. biologic disease- modifying antirheumatic drugs (bDMARD) in Korean patients with rheumatoid arthritis (RA) who ha...
A quasi-experimental, multi-center, prospective, non-randomized study was conducted to compare response rates between JAKi and bDMARDs in patients with RA naïve to targeted therapy. An interim analysi...
Among 506 patients enrolled from 17 institutions between April 2020 and August 2022, 346 (196 JAKi group and 150 bDMARD group) were included in the analysis. After 24 weeks of treatment, 49.0% of JAKi...
Our interim findings reveal JAKi have comparable effectiveness and safety to bDMARDs at 24 weeks after treatment initiation....
Rheumatoid arthritis (RA) increases the risk of cardiovascular disease (CVD), with inflammation playing a key role. Biologic and targeted synthetic drugs used to treat RA can induce systemic immunomod...
A systematic review of the literature was conducted to investigate the impact of biologic and targeted synthetic treatments approved for RA on various cardiovascular markers, including endothelial fun...
From an initial pool of 647 records, we excluded 327 studies based on their titles and abstracts, and we selected 182 studies for final examination. Ultimately, 58 articles met our inclusion criteria ...
Overall, our systematic review provides important insights into the potential cardiovascular benefits of biologic and targeted synthetic treatments for RA by a still unknown mechanism. These findings ...
Most women with rheumatic diseases discontinue antirheumatic therapies in anticipation of, or during pregnancy due to concerns around medication safety and fetal wellbeing....
We performed a scoping review of available evidence investigating the risks of adverse offspring neurodevelopmental outcomes amongst parents with chronic inflammatory arthritis, taking antirheumatic t...
We designed a scoping review protocol and search strategy a priori in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We performed an exhaustive...
Six studies were included for full data abstraction. Use of Nonsteroidal Anti-inflammatory Drugs, Tumor Necrosis Factor Alpha inhibitors, and exposure to methotrexate during early first trimester of p...
Use of some antirheumatic therapies during pregnancy may not be associated with adverse offspring neurodevelopmental outcomes. Further investigations are needed to elucidate if other confounding facto...
The treatment of immune-mediated inflammatory diseases (IMIDs) is one of the main challenges of modern medicine. Although a number of disease-modifying antirheumatic drugs (DMARDs) are available, ther...
The advent of biologic disease modifying antirheumatic drugs (bDMARDs) has considerably improved patient outcomes in inflammatory arthritis. However, not all patients reach the state of remission, as ...
The prevalence of chronic pain is high in patients with rheumatoid arthritis (RA), increasing the risk for opioid use. The objective of this study was to assess disease-modifying antirheumatic drug (D...
This cohort study included Medicare beneficiaries with diagnosis of RA who received at least 30-day consecutive prescription of opioids in 2017 (n = 23,608). The patients were grouped into non-DMARD a...
Compared with non-DMARD users, the odds of long-term opioid use were significantly lower among DMARD users (odds ratio, 0.89; 95% confidence interval, 0.83-0.95). All regimens except non-tumor necrosi...
Disease-modifying antirheumatic drug use was associated with lower odds of long-term opioid use among RA patients with baseline opioid prescription. Factors associated with non-DMARD use represent a w...
Biologics and Janus kinase (JAK) inhibitors play an important role in the treatment of rheumatoid arthritis. As new therapeutic developments have emerged in recent decades, the morbidity and mortality...
Current data are lacking regarding the risk of biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) use on the development of interstitial lung disease (ILD) in patients wi...
To determine the risk of developing ILD in patients with RA undergoing treatment with different b/tsDMARDs....
Retrospective cohort study using claims data from the Optum Clinformatics Data Mart between December 2003 and December 2019. Adult patients with RA, 1 year or more of continuous enrollment, treatment ...
New administration of adalimumab, abatacept, rituximab, tocilizumab, or tofacitinib....
Crude incidence rates (IRs) for the development of ILD were calculated. The risk of ILD across different b/tsDMARDs was compared using Cox-regression models. A sensitivity analysis using a prevalent n...
A total of 28 559 patients with RA (mean [SD] age 55.6 [13.7] years; 22 158 female [78%]) were treated with adalimumab (13 326 patients), abatacept (5676 patients), rituximab (5444 patients), tocilizu...
In this retrospective cohort of patients with RA, patients treated with tofacitinib had the lowest incidence of ILD compared with patients treated with all bDMARDs evaluated, and patients treated with...